BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260322
DTEND;VALUE=DATE:20260326
DTSTAMP:20260429T170211
CREATED:20260122T141811Z
LAST-MODIFIED:20260312T111337Z
UID:36486-1774137600-1774483199@senzagen.com
SUMMARY:2026 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #1934\nSan Diego\, CA\, USA\nJoin our scientific sessions and poster presentations at this year’s SOT\, featuring the latest GARD® data and case studies generated in collaboration with industry leaders. \nMeet us at booth #1934 and discuss your specific testing needs with our scientific team – We help you design testing strategies tailored to your substances and regulatory goals: from “2 out of 3” defined approaches according to OECD 497\, to exploratory studies supporting product development. \n \nExhibitor-Hosted Session\nAdvancing NAMs for Skin and Respiratory Sensitization: UVCBs\, Natural Extracts and Medical Devices \nNew GARD® advances in respiratory sensitization\,  ISO 10993-10 compliance for medical devices\, quantitative potency assessment\, and difficult-to-test samples \nRoom 23A | Tue\, 24 March | 10:45 am-11:45 am\n \n1. Introduction to GARD® technology for skin and respiratory sensitization testing \n🎤Andy Forreryd\, PhD |  Scientific Liaison\, SenzaGen  \n2. Evaluating sensitization potential of medical devices in vitro using GARD®skin assay: a practical in vitro sensitization case study in medical device development \n🎤Yizhong Liu\, PhD\, DABT | Senior Scientist and Toxicologist\, Johnson & Johnson MedTech  \n3. GARD®air for the prediction of respiratory sensitization for substances of regulatory concern \n🎤Emily Reinke\, PhD\, DABT | Principal Toxicologist\, GDIT (contractor supporting NICEATM)  \n4. Respiratory sensitization hazard identification: navigating assay exploration for biocatalytic enzymes \n🎤Joshua Vaughan\, PhD\, DABT | Principal Scientist\, Merck  \nSpeaking in Symposium Sessions\nIn Vitro Testing for Skin Sensitization of Mixtures: Where Science Stands Today \nRoom 7B | Wed\, 25 March | 8:00 am-10:45 am \nChairs: The Honest Company\, Edgewell Personal Care | SenzaGen: Dr Tim Lindberg | SenzaGen: Dr Tim Lindberg \nHuman Health Risk Assessments of Biopesticides: Evaluating Safety for Agricultural Use \nBallroom 6F | Wed\, 25 March | 1:30 PM-4:15 PM \nChairs: Bayer Crop Science\, Corteva Agriscience | SenzaGen: Dr Andy Forreryd \nPosters\n🎫 K764 | #5200 | Case study: Fragrance formulations – Jointly with Coty \nImproving the safety profiles of fragrance formulations: modulating the skin sensitization potential to reduce or eliminate the risk of allergic skin reactions \n🎫 K762 | #5198 | Case study: 2o3 DA applied to UVCBs – Jointly with ExxonMobil \nApplying the “2 out of 3” Defined Approach (OECD 497) to assess skin sensitization potential of UVCBs using the GARD®skin and EpiSensA assays \n🎫 K759 | #5195 | Case study: NESIL prediction for OTC drugs – Jointly with Haleon  \nPredicting NESIL using New Approach Methodologies: a case study on quantitative skin sensitization assessment of topical over-the-counter pharmaceutical candidates \n🎫B175 | #3072 | Medical Device ISO 10993-10 \nIn vitro sensitization assessment of medical device extracts: Prevalidation results of GARD®skin Medical Device for potential inclusion in ISO 10993-10 \n🎫G546 | #3403 | New alternative gene expression platform for GARD® \nRNA-seq can be used for gene expression quantification in the GARD®skin method for assessment of skin sensitizers
URL:https://senzagen.com/event/2026sot/
LOCATION:San Diego\, CA\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/01/2026-SOT-eventpage-banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251106
DTEND;VALUE=DATE:20251108
DTSTAMP:20260429T170211
CREATED:20250828T142424Z
LAST-MODIFIED:20251028T132753Z
UID:35451-1762387200-1762559999@senzagen.com
SUMMARY:3rd Annual Medical Device Biocompatibility Conference
DESCRIPTION:3rd Annual Medical Device Biocompatibility Conference\n Berlin\, Germany |  Nov 6-7\nCome meet us at this year’s Medical Device Biocompatibility Conference in Berlin\, where SenzaGen’s chief scientist Henrik Johansson will present recent progress in applying New Approach Methodologies (NAMs) for skin sensitization testing within the ISO 10993 framework\, including current regulatory developments and data from GARD®skin for Medical Devices. \nOur group company ToxHub will also present\, sharing insights on regulatory strategies for substance-based medical devices in line with MDR\, while VitroScreen will attend to discuss testing approaches\, including support for mode of action and classification. \nWant to connect with our scientific team while you’re there? \n \nPresentations\n“Building Confidence in New Approach Methodologies (NAMs) for Skin Sensitization Testing of Medical Devices”\n Thursday\, 6th Nov | 13:30 – 14:00 CET\n👤 Speaker: Dr Henrik Johansson\, Chief Scientist at SenzaGen\nKey takeaways:\n\nIntroduction to in vitro biocompatibility testing: Overview of available assays and their regulatory status.\nPre-validation data from GARD®skin for Medical Devices: In vitro skin sensitization testing of Medical Device Extracts for implementation in ISO 10993-10.\nRegulatory Developments in ISO 10993-10: Inclusion of in vitro methods.\nCase study: Integrating in vitro data into CE-marking submissions.\n\n\n“Biocompatibility evaluation of substance-based medical devices”\n Friday\, 7th Nov | 11:40 – 12:10 CET\n👤 Speaker: Dr Carla Landolfi\nKey takeaways:\n\nOverview of biocompatibility evaluation for substance-based medical devices under ISO 10993 and MDR.\nTesting strategies: in vitro\, in vivo\, and non-testing approaches.\nRegulatory challenges and best practices for ensuring patient safety.
URL:https://senzagen.com/event/3rd-annual-medical-device-biocompatibility-conference/
LOCATION:Berlin\, Germany
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/MD-Biocompatibility-conference-in-Berlin-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251021
DTEND;VALUE=DATE:20251024
DTSTAMP:20260429T170211
CREATED:20250828T140923Z
LAST-MODIFIED:20250828T193940Z
UID:35446-1761004800-1761263999@senzagen.com
SUMMARY:ASCCT 2025
DESCRIPTION:ASCCT 14th Annual Meeting\n📍 Gaithersburg\, USA | 🗓 October 21–23\, 2025\nMeet us at this year’s ASCCT annual meeting in Gaithersburg\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nMore information coming soon!
URL:https://senzagen.com/event/ascct-2025/
LOCATION:Gaithersburg\, Md\, USA
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/08/25133-RAD-ASCCT-Annual-Meeting-Graphics_IIVS-Update-1584x396-1-e1756392285881.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251015
DTEND;VALUE=DATE:20251019
DTSTAMP:20260429T170211
CREATED:20250828T135526Z
LAST-MODIFIED:20250828T195046Z
UID:35428-1760486400-1760831999@senzagen.com
SUMMARY:ICT/IUTOX 2025
DESCRIPTION:ICT 2025 / IUTOX 17th International Congress of Toxicology\n📍 Beijing\, China | 🗓 October 15–18\, 2025\nMeet us at this year’s ICT/IUTOX conference in Beijing\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nPosters\n🎫  #645 | Quantitative skin sensitization potency assessment\nAdvancing in vitro skin sensitization potency assessment using GARDskin Dose-Response \n🎫 #649 | Application for medical devices\nPre-validation results from GARDskin for Medical Devices: In vitro sensitization testing of medical device extracts for implementation in ISO 10993-10
URL:https://senzagen.com/event/ict-iutox-2025/
LOCATION:Beijing\, China
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/ICT-banner-e1756389255388.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250929T100000
DTEND;TZID=Europe/Stockholm:20250929T190000
DTSTAMP:20260429T170211
CREATED:20250828T131114Z
LAST-MODIFIED:20250828T194205Z
UID:35415-1759140000-1759172400@senzagen.com
SUMMARY:RIFM INFOX 2025
DESCRIPTION:RIFM 2025 Information Exchange (INFOX®) Paris\nFrance Advancing Fragrance Safety Through Innovation\, Science\, and Collaboration\nDate: September 29\, 2025\nLocation: Le Méridien Etoile\, 81 Bd Gouvion-Saint-Cyr\, 75017 Paris\, France\nCome meet SenzaGen’ skin sensitization experts Dr Andy Forreryd and Dr Tim Lindberg at this year’s Research Institute for Fragrance Materials (RIFM) INFOX© meeting in Paris! \nThis exclusive event brings together leading scientists to present the latest advancements in fragrance safety science\, spanning human health and environmental protection. INFOX 2025 is a key forum for shaping the future of safe and sustainable fragrance use\, and we look forward to engaging in the discussions. \nWant to connect with our scientific team while you are in Paris?
URL:https://senzagen.com/event/rifm-infox-2025/
LOCATION:Paris\, France
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/INFOX-GENERAL-HEADER-1024x535-1-e1756387095780.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250914
DTEND;VALUE=DATE:20250918
DTSTAMP:20260429T170211
CREATED:20250317T151319Z
LAST-MODIFIED:20250909T111839Z
UID:34391-1757808000-1758153599@senzagen.com
SUMMARY:Eurotox 2025
DESCRIPTION:Eurotox 2025\n Athens\, Greece |  Sep 14-17\nBooth #A24\nAdvancing NAMs for Skin Sensitization Testing\nCome meet us at this year’s Eurotox and take part in our scientific activities\, featuring an industry-hosted session\, poster presentations\, and the latest insights on GARD®. Discover how the method provides high performance\, broad applicability\, and quantitative potency information for skin sensitization testing. \nWant to connect with our scientific team while you’re there? \n \nIndustry-Hosted Session\nRegulatory update: GARD®skin in OECD TG 497\nTime: 12:00-13:00 | Tuesday\, September 16\nVenue: N. Skalkotas Hall\n \nJoin us for an interactive scientific session featuring regulatory updates\, case studies\, and a live Q&A. Key highlights: \n\nRegulatory update: GARD®skin included in OECD TG 497.\nCase studies: UVCBs\, Natural Extracts\, Formulations\, Hydrophobic Substances\, and more.\nScientific collaborations: dōTERRA\, BIC\, and Urgo.\n\nLearn how GARD®skin fits into TG 497 and what this means in practice for your regulatory testing strategy. \nPosters\nSpotlight on Essential oils\, Safe dose levels\, Hypoallergenic claims and more\n🎫 P32-09 #644 | Joint poster with DōTERRA\nComparative analysis of skin sensitization thresholds for essential oils: human\, murine\, and GARDskin Dose-Response \n🎫 P32-12 #731 | Joint poster with BIC Skin Creative\nIn vitro skin sensitization potency assessment using GARDskin Dose-Response: a case study on natural extracts-based skin-binding dyes and dye precursors \n🎫 P32-16 #923 | Joint poster with Urgo\nSupporting industry decision-making and hypoallergenicity claims using an experimental setup combining GARDskin Medical Device and Dose-Response protocols \n🎫 P23-04 #314 | ToxHub poster\nDeriving gender-sensitive Occupational Exposure Limits: Case studies on benperidol and dimethylacetamide \nMore at our booth\nExpert guidance for your regulatory challenges\nMeet ToxHub\, our consultancy unit specializing in toxicological risk assessment and regulatory strategy consulting\, with expertise across medical devices\, pharmaceuticals\, cosmetics and chemicals. \nDiscover how ToxHub can support your needs
URL:https://senzagen.com/event/eurotox-2025/
LOCATION:Athens\, Greece
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025-eurotox-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250831
DTEND;VALUE=DATE:20250905
DTSTAMP:20260429T170211
CREATED:20250303T121220Z
LAST-MODIFIED:20250828T194641Z
UID:34240-1756598400-1757030399@senzagen.com
SUMMARY:WC13
DESCRIPTION:13th World Congress on Alternatives and Animal Use in the Life Sciences\n📍 Rio de Janeiro\, Brazil | 🗓 Aug 31-Sep 4\nAt this year’s conference SenzaGen and Unilever co-chair a scientific symposium\, where Dr Andy Forreryd will present how GARD® can be applied to derive a Point-of-Departure (PoD) for quantitative skin sensitization assessment. \n \nSession #79\nUsing NAMs to derive PoDs for NGRA of skin sensitizers: Towards regulatory implementation\nTime: 9:30-11:00 | Tuesday\, September 2\nVenue: Plenary Room\nTogether with speakers from Unilever\, Research Institute for Fragrance Materials (RIFM)\, and Inotiv\, this joint symposium will cover methodological innovations in New Approach Methodologies (NAMs)\, industry case studies on deriving Points of Departure (PoDs) for fragrances\, and the challenges and opportunities for regulatory acceptance. \n \n💻 Incorporating expert knowledge in the Skin Allergy Risk Assessment (SARA) Model: an integrated approach to testing and assessment (IATA) demonstrated in case studies.\nRenato Ivan de Ávila\, PhD @Unilever \n💻 The GARD®skin Dose-Response model to derive a PoD for quantitative skin sensitization assessment.\nAndy Forreryd\, PhD @SenzaGen \n💻 Predicting PoD and potency categories using New Approach Methods: Practical experience from the fragrance industry.\nIsabella Schember\, PhD @Research Institute for Fragrance Materials (RIFM) \n💻 Integrating NAMs for quantitative skin sensitization potency assessment into regulatory frameworks: experience from the work in OECD TG 497\nEmily Reinke\, PhD\, D.A.B.T @Inotiv \nPoster #167\nGARD®skin for Medical Devices: Pre-validation results for implementation in ISO 10993-10\nThe pre-validation study of GARD®skin Medical Device confirms the method is functional\, reproducible and sufficiently accurate to proceed to the validation study phase\, as defined by the ISO TS11796.
URL:https://senzagen.com/event/wc13/
LOCATION:Rio de Janeiro\, Brazil
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/WC13-Logo-white-background.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250411
DTSTAMP:20260429T170211
CREATED:20250317T145617Z
LAST-MODIFIED:20250317T150648Z
UID:34382-1743724800-1744329599@senzagen.com
SUMMARY:In-cosmetics Global 2025
DESCRIPTION:Meet us at In-cosmetics global in Amsterdam!  \nDate: April 8-10\, 2025
URL:https://senzagen.com/event/2025in-cosmetics-global/
LOCATION:Amsterdam\, Netherlands
CATEGORIES:Conference
ATTACH;FMTTYPE=image/webp:https://senzagen.com/wp-content/uploads/2025/03/INCOS-Global_370x125_Atlas-logo.png.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250405
DTSTAMP:20260429T170211
CREATED:20250317T134428Z
LAST-MODIFIED:20250317T145119Z
UID:34368-1743724800-1743811199@senzagen.com
SUMMARY:2025 SFT annual meeting
DESCRIPTION:Meet us at Swedish Society of Toxicology (SFT)’s annual meeting in Stockholm! This year the theme is “Breaking boundaries: novel methods and approaches advancing toxicology”. \nDate: April 4\, 2025 \nVenue: Samuelssonssalen\, Karolinska Institutet\, Tomtebodavägen 6\, Solna \nSenzaGen’s presentation: Advancing skin sensitization testing with GARD®: Enhancing human relevance and overcoming regulatory challenges \nSpeaker: Tim Lindberg\, PhD\, In vitro Toxicology Expert\, SenzaGen
URL:https://senzagen.com/event/2025sft/
LOCATION:Stockholm\, Sweden
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/03/KI_Samuelssonssalen-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250331
DTEND;VALUE=DATE:20250402
DTSTAMP:20260429T170211
CREATED:20250303T115948Z
LAST-MODIFIED:20250317T085841Z
UID:34234-1743379200-1743551999@senzagen.com
SUMMARY:Forum SOFHYT 2025
DESCRIPTION:Meet us at the SOFHYT (French Society of Occupational Hygienists) forum “From Prevention to Action: The Occupational Hygienist at the Heart of Occupational Health Risk Management” in Paris on March 31 and April 1. \nOral presentation | 1 April
URL:https://senzagen.com/event/sofhyt2025/
LOCATION:Paris\, France
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/Forum-SOFHYT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20250328
DTSTAMP:20260429T170211
CREATED:20250303T114445Z
LAST-MODIFIED:20250317T083038Z
UID:34229-1742947200-1743119999@senzagen.com
SUMMARY:6th Annual BTEL Summit & Exhibition
DESCRIPTION:Meet us at the 6th Annual BTEL Summit & Exhibition in Berlin. \nOral presentation | 26 March \nBuilding confidence in New Approach Methodologies (NAMs) for biological safety testing of Medical Devices: a successful case study on skin sensitization testing using GARD®  \nAndy Forreryd\, PhD\nScientific Liaison Manager\, SenzaGen
URL:https://senzagen.com/event/btel2025/
LOCATION:Berlin\, Germany
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025BTEL-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250316T080000
DTEND;TZID=Europe/Stockholm:20250320T170000
DTSTAMP:20260429T170211
CREATED:20250207T084353Z
LAST-MODIFIED:20250312T122014Z
UID:34052-1742112000-1742490000@senzagen.com
SUMMARY:2025 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #637 \nOrange County Convention Center\,  Orlando\, FL. \nMeet us and discover how the GARD® assays are transforming skin sensitization testing. Learn about their role in filling data gaps for in vitro skin sensitizing hazard and quantitative potency assessment\, providing a high-performing and ethical alternative to animal testing. \nExhibitor-Hosted Session\nAdvancing NAMs for Skin Sensitization Testing: Potency\, Challenging Substances and Medical Devices \nW208B | Tuesday\, 18 Mar | 10:45 am-11:45 am \n \n  \nBring your questions and testing challenges!\n \nJoin us for an interactive session that combines essential regulatory updates\, case studies\, and a live Q&A! Gain exclusive insights on the latest GARD®data from SenzaGen’s research and industry collaborations\, including key advancements in testing challenging substances\, medical devices\, and quantitative potency assessment. We will also share user cases from industry leaders like dōTERRA\, Clarins\, and Bic Skin Creative. \nOur experts will be available to discuss how GARD® innovations can address your needs and advance your work in skin sensitization testing. \nKey Topics \n\nNew GARD® data from industry collaborations on Natural Extracts and Quantitative Potency Assessment.\nRegulatory update WG8 ISO TC194: Medical Devices ISO 10993-10.\nUser Cases from dōTERRA\, Clarins\, Bic Skin Creative\, and more.\n\nSpeakers \n\nRon Brown\, Toxicologist at Risk Science Consortium (former FDA reviewer for Medical Devices)\nJoe Dawson\, Product Safety Manager at doTERRA International\nAndy Forreryd\, Scientific Liaison\, SenzaGen\n\nPosters\n🎫 G367 | Skin Sensitization Potency GHS/CLP Classification \nMarch 17\, 1:45 pm -4:15 pm | #3242 Subcategorization of skin sensitizers into UN GHS categories using GARD®skin Dose-Response \n🎫 D217 | Medical Devices Testing ISO 10993-10 \nMarch 19\, 9:15 am -11:45 am | #4382 Pre-validation Results from GARD®skin for Medical Devices: In Vitro Sensitization Testing of Medical Device Extracts for Implementation in ISO 10993-10 \n🎫 LB352 | NAMs in Occupational Health – Joint poster with Lundbeck \nMarch 20\, 8:30 am -11:30 am | #5251 Assessing skin sensitizing hazard of Drug Products and Active Pharmaceutical Ingredients using GARD®: New Approach Methodology in Occupational Health and Safety \n🎫 F310 |  Application for Pharmaceuticals – Joint poster presented by SafeBridge \nMar 18\, 1:45 pm-4 pm | #3838 Comparison of β-lactam ring containing substances gene expression signatures related to therapeutic mechanism and the Adverse Outcome Pathway (AOP) for sensitization \n 
URL:https://senzagen.com/event/2025sot/
LOCATION:Orlando\, Fl\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/02/2025-SOT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241031
DTSTAMP:20260429T170211
CREATED:20240905T122507Z
LAST-MODIFIED:20250317T085918Z
UID:33088-1730073600-1730332799@senzagen.com
SUMMARY:ASCCT 13th Annual Meeting
DESCRIPTION:Meet us at the American Society for Cellular and Computational Toxicology (ASCCT) Annual Meeting in Research Triangle Park\, North Carolina. \n  \nOral presentation | Monday\, 28 October | 17:20-17:35\nNAMs for botanical safety evaluation: Case Study on Determine the Safe Use Levels of Genipa Plant Extract in Temporary Tattoo Ink with GARD®\n  \nPoster\nGARD®skin Dose-Response for skin sensitizing potency assessment: Performance on the Reference Chemical Potency List (RCPL)
URL:https://senzagen.com/event/ascct-13th-annual-meeting/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/24050-RAD-ASCCT-13th-Annual-Meeting-Graphics-1584x39676_Page_1-scaled-e1725539063290.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240908T080000
DTEND;TZID=Europe/Stockholm:20240911T170000
DTSTAMP:20260429T170211
CREATED:20240126T092505Z
LAST-MODIFIED:20240905T105818Z
UID:31912-1725782400-1726074000@senzagen.com
SUMMARY:Eurotox 2024
DESCRIPTION:Meet us at Booth #56\nCome meet us at booth #56 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps in skin sensitizing hazard and quantitative potency assessment. Additionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \n  \n \nIndustry-Hosted Session\n“Advancing NAMs for Skin Sensitization” \nGuest speakers from Lundbeck and Unilever\n \nPosters\nSpotlight on Hydrophobic Esters\, PoD\, Defined Approaches\, and more\n🎫 P01-79 #996 | Joint poster with Cargill\nThe applicability of GARD®skin for assessing skin sensitization potential of hydrophobic esters during product development \n🎫 P19-57 #661 | Joint poster with L’Oréal\nImproved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 P19-75 #840 | Joint poster with Sonova\nIntegrating NAMs into early-stage screening of novel materials intended for use in Medical Devices: Case studies on the use of GARD® for in vitro skin sensitization assessment \n🎫 P20-17 #613 | SenzaGen poster\nGARD®skin as a drop-in replacement KE3-method in OECD GD 497 Defined Approaches \n🎫 P23-21 #937 | ToxHub poster\nWorkflow for Occupational Exposure Limit Determination and Banding: Focus on Skin and Respiratory Sensitization using NAMs approaches \n🎫 LP-28 | ToxHub poster\nRisk Assessment Approaches for Nanomaterials in Medical Devices \n 
URL:https://senzagen.com/event/eurotox2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/Lime-banner-new-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240603T080000
DTEND;TZID=Europe/Stockholm:20240606T170000
DTSTAMP:20260429T170211
CREATED:20240126T091543Z
LAST-MODIFIED:20240521T140249Z
UID:31906-1717401600-1717693200@senzagen.com
SUMMARY:ESTIV Congress 2024
DESCRIPTION:Come meet us at booth #22 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment.  \nAdditionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \nPresentations and Posters\nOur team will showcase several posters and presentations. Dive into new scientific data and discover exciting projects done in collaboration with industry partners. \nTuesday 09:00-10:30 | Presentation in Session 2b\nProject in collaboration with L’Oreal. “Improved confidence of quantitative sensitizing potency assessment for PoD using GARD®skin Dose-Response”\n\nThursday 11:30-12:45 | Presentation in Session 9a\n“Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment” \nPoster | Presented by ToxHub\n#334 | “Integrated Risk Assessment and Compliance Strategies for Nanomaterials in Medical Devices”
URL:https://senzagen.com/event/estiv-congress-2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/ESTIV-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240310T080000
DTEND;TZID=Europe/Stockholm:20240314T170000
DTSTAMP:20260429T170211
CREATED:20231115T134814Z
LAST-MODIFIED:20240306T094116Z
UID:31573-1710057600-1710435600@senzagen.com
SUMMARY:2024 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #732\nDiscuss your testing needs with us\n  \nExhibitor-Hosted Session\nExpert round table on NAMs and industry trends\nTuesday\, 12 Mar | 9:00 am-10:00 am\n \n \nPosters\nSpotlight on PoD\, NESILs\, product development and CE-marking of Medical Devices\nMonday\, 11 Mar | 9:15 am-11:15 am\n🎫 Joint poster with Sonova\nP487 #3362 | Unveiling skin sensitizing potential: case studies on biocompatible material development utilizing the in vitro GARD®skin Medical Device assay \n🎫 Joint poster with Duearity\nP480 #3355 | Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment \n🎫 Joint poster presented by RIFM\nP318 #3205 | Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARD®skin Dose-Response assay \nTuesday\, 12 Mar | 2:15 pm-4:15 pm\n🎫 Joint poster with L’Oréal\nP739 #4190 | Improved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 Joint poster presented by IFF\nP762 #4213 | A Next Generation Risk Assessment (NGRA) Framework to conduct Quantitative Risk Assessment (QRA2) to determine safe use levels of fragrance ingredients in cosmetic products \n🎫 Joint poster presented by Inotiv\nP738 #4189 | Testing of Regulatory-Relevant Chemicals for Skin and Respiratory Sensitization Hazard \n\n 
URL:https://senzagen.com/event/sot-annual-meeting-2024-toxexpo/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/11/SOT2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20260429T170211
CREATED:20230824T070701Z
LAST-MODIFIED:20231109T141151Z
UID:30935-1699747200-1700092799@senzagen.com
SUMMARY:ACT 2023 Annual Meeting
DESCRIPTION:→ Booth #333\nSpotlight on difficult-to-test samples and in vitro quantitative potency assessment as an alternative to the Local Lymph Node Assay\nCome meet us at booth #333 and join our poster presentation to learn how the GARD assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment\, providing a high performing and ethical alternative to animal testing. \n→ Joint poster with Takasago\nQuantitative potency assessment of skin sensitizers when developing novel fragrance ingredients\nPractical application of the GARDskin Dose-Response assay to derive a No Expected Sensitization Induction Level (NESIL) value for confirmatory human patch studies to determine safe use level for novel fragrance ingredients \n→ Hot topic\nIn vitro tests supporting Occupational Health\nOccupational allergic dermatitis and asthma are common workplace diseases. By using the in vitro GARD® assays to test for skin and respiratory sensitizers in combination\, it is possible to identify allergens in the work environment and take preventive action. \nCome by our booth to learn more! \n→ Discuss your toxicological risk assessment needs with us!\nMeet our in vitro experts\, Dr Andy Forreryd and Dr Tim Lindberg
URL:https://senzagen.com/event/act-2023-annual-meeting/
LOCATION:Orlando\, Florida\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/banner_ACT2023-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230910T080000
DTEND;TZID=Europe/Stockholm:20230923T170000
DTSTAMP:20260429T170211
CREATED:20230313T144734Z
LAST-MODIFIED:20230831T110511Z
UID:30473-1694332800-1695488400@senzagen.com
SUMMARY:Eurotox 2023
DESCRIPTION:New opportunities for skin sensitization testing with GARD®skin OECD TG 442E\nCome meet us at booth #36 and join our poster presentations to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development.\nMeet also ToxHub\, our latest addition to the Group\, and benefit from expert Toxicology and Regulatory advice.\nBooth #36\n\nDiscuss your toxicological risk assessment needs with us!\n\n \n \nPosters\n\nSpotlight on Difficult-to-Test\, Quantitative Potency\, Medical Devices and E&L Assessment\n\n→ Joint poster with Exxon Mobil\nP07-02 | Assessing the utility of the Genomic Allergen Rapid Detection (GARD®skin) assay to detect dermal sensitization potential in UVCBs and formulated lubricant products \n→ Joint poster with IFF and RIFM\nP22-43 | The GARD® skin Dose-Response assay for determination of a point-of-departure (PoD) for Next Generation Risk Assessment (NGRA) of skin sensitizers: A case study using isocyclocitral \n→ Joint poster with Duearity\nP22-30 | Regulatory approval of medical devices according to MDR using in vitro data from GARD® skin Medical Device for skin sensitization assessment \n→ ToxHub poster\nLP-38 | Toxicological risk assessment of extractable and leachable compounds: mitigating risks in pharmaceutical applications \nNew\n\nTailored Toxicology Services\n\nAt our booth\, you will also meet our independent consultancy unit Toxhub\, specialized in toxicological risk assessment and regulatory strategy consulting\, with expertise in pharmaceuticals\, chemicals\, medical devices and cosmetics. \nExplore ToxHub’s services \n 
URL:https://senzagen.com/event/eurotox-congress-2023/
LOCATION:Ljubljana\, Slovenia\, Slovenia
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/03/Eurotox23v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230831T080000
DTEND;TZID=Europe/Stockholm:20230904T170000
DTSTAMP:20260429T170211
CREATED:20230313T144259Z
LAST-MODIFIED:20230831T105454Z
UID:30467-1693468800-1693846800@senzagen.com
SUMMARY:WC12
DESCRIPTION:12th World Congress on Alternatives and Animal Use in the Life Sciences\nOur team and partners will feature the GARD® assays in several posters and presentations. Join us to explore new scientific data and exciting projects done in collaboration with industry partners.\nSymposia\n\nSpotlight on Medical Devices\, Complex Samples and Dose-Response\n\nWednesday\, Aug 30\, 11:00 – 12:30\, Session S410\n→ In collaboration with Duearity\n#515 Application of the GARD®skin Medical Device assay for regulatory approval of medical devices according to MDR \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ In collaboration with RIFM and IFF\n#208 In vitro determination of a point of departure for Next Generation Risk Assessment (NGRA) of skin sensitizers: Reproducibility and precision of the GARD®skin Dose-Response assay \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ Presented by Emily N Reinke\, Inotiv-RTP\, in collaboration with NIH and Burleson Research Technologies\n#90 Evaluating Skin Sensitization Hazard of Diverse Chemicals Using GARD®skin \nPosters\n\nSpotlight on Complex Mixtures\, Metals and Protein Allergens\n\nTuesday\, Aug 29\, 12:30 – 14:00\n→ Joint poster with Corteva Agriscience\nA33 #230 | GARD®: a study to investigate the applicability domain for agrochemical formulations \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Johnson Matthey\nF81 #55 | Expanding the applicability domain of NAMs for skin sensitization testing: a case study using GARD®skin for assessment of metals \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Merck\nF80 #498 | Characterization of respiratory sensitizing properties of the protein Subtilisin\, using GARD®air \nMeet our team\n\nMeet and greet with Andy Forreryd
URL:https://senzagen.com/event/12th-world-congress-on-alternatives-and-animal-use-in-the-life-sciences-wc12/
LOCATION:Niagara Falls\, Canada\, Niagara Falls\, Canada
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Number-logo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230322T080000
DTEND;TZID=Europe/Stockholm:20230323T170000
DTSTAMP:20260429T170211
CREATED:20221109T100611Z
LAST-MODIFIED:20230322T130845Z
UID:30088-1679472000-1679590800@senzagen.com
SUMMARY:2023 SOT Annual Meeting & ToxExpo
DESCRIPTION:Meet us at this year’s SOT\nCome meet us at our booth and join our hosted session to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development. \n \n  \n  \n\nExhibitor-Hosted Session\n\n\n  \n  \n\nPosters\n\n🎫 P117 |  Joint poster with ExxonMobil Biomedical Sciences\n#3016: Mar 20\, 9:00am-10:45am: Assessing the Utility of the Genomic Allergen Rapid Detection (GARDskin) Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products \n🎫 P329 | Joint poster with Research Institute for Fragrance Materials (RIFM)\n#4456: Mar 22\, 10:45am-12:30pm: GARDskin Dose-Response for Photosensitization: Assessment of Reference Photoirritants and Photoallergens \n🎫 P293 | Poster on Medical Device\n#4422: Mar 22\, 10:45am-12:30pm: In Vitro Assays for Assessment of Skin Sensitization Hazard and Potency of Isobornyl Acrylate \n🎫 P151 | Joint poster with International Flavors & Fragrances Inc. (IFF) and Research Institute for Fragrance Materials (RIFM)\n#5050: Mar 23\, 8:30am-11:30am: Gardskin Dose-Response Assay for Pod Determination of Fragrance Materials and Its Application in Conducting Quantitative Risk Assessment (QRA) \n\nExpanded toxicology testing services\n\nAt our booth\, we will introduce you to how you can use in vitro methods for the biological evaluation of medical devices and how we can support you with tailored toxicology advisory services. We will also present our expanded services for in vitro regulatory toxicity testing. \nFind out about our expanded services and expertise\n 
URL:https://senzagen.com/event/2023-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/Newsletter-banner-SOT.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230215
DTEND;VALUE=DATE:20230218
DTSTAMP:20260429T170211
CREATED:20230111T132555Z
LAST-MODIFIED:20230111T154919Z
UID:30279-1676419200-1676678399@senzagen.com
SUMMARY:PCHi 2023 Expo & SHSOT Forum
DESCRIPTION:Personal Care and Homecare Ingredients 2023 Expo & Shanghai Society of Toxicology Forum\n15-17 February 2023 @The China Import and Export Fair Complex\, Guangzhou\, China\nRead More
URL:https://senzagen.com/event/pchi-2023-expo-shsot-forum/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/msg98-1-2022-07-21-5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260429T170211
CREATED:20221021T092257Z
LAST-MODIFIED:20221128T115912Z
UID:29974-1669852800-1670025599@senzagen.com
SUMMARY:2022 Aromadays
DESCRIPTION:Dec 1-2 | Avignon\, Palais des Papes\, France\nMeet us at the 2022 Aromadays conference in Avignon and talk to our specialists regarding the application of the GARD assays for essential oils. \nScientific session\n09:45 CET\, Dec 2\, 2022\nAre there limitations to the applicability of toxicological tests to essential oils ? Focus on the GARD®skin test\nExiste-t-il des limites à l’application des tests toxicologiques aux Huiles Essentielles? Focus sur le test GARD®skin\nCristina ONCINS PALLAS\, Chargée de l’évaluation toxicologique des ingrédients – CONSORTIUM HE\nDr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen\nRead more here
URL:https://senzagen.com/event/2022-aromadays/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/10/logo_aromadays.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221124T080000
DTEND;TZID=Europe/Stockholm:20221125T170000
DTSTAMP:20260429T170211
CREATED:20221102T083023Z
LAST-MODIFIED:20221121T123857Z
UID:30037-1669276800-1669395600@senzagen.com
SUMMARY:2022 SFT
DESCRIPTION:Nov 24-25 | Avignon\, France\nMeet us at the 2022 annual meeting of the French Society of Toxicology in Avignon and talk to our skin sensitization experts regarding the new opportunities the GARD assays have brought to the field. \nWe will also present a poster: “Quantitative sensitizing potency assessment using GARD®skin Dose-Response”. \nPresented by: Dr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen
URL:https://senzagen.com/event/2022-sft/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/logo_sft.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221121
DTEND;VALUE=DATE:20221126
DTSTAMP:20260429T170211
CREATED:20220825T140904Z
LAST-MODIFIED:20221114T140547Z
UID:29773-1668988800-1669420799@senzagen.com
SUMMARY:2022 ESTIV
DESCRIPTION:Booth#5 | Nov 21-25 | Sitges (Barcelona)\, Spain\nAre you attending the 2022 ESTIV International Congress? Come meet us at our booth and join our scientific sessions to hear the latest news about GARD and how the assays are used for skin sensitization testing. We will also introduce you to our expanded services for in vitro regulatory toxicity testing and how you can use in vitro methods for the biological evaluation of medical devices. \n\nScientific presentations\n\n“In vitro assessment of skin sensitizing potential of process-related impurities in polymeric materials during product development”\nSpeaker:  Dr Andy Forreryd @SenzaGen \nTuesday\, November 22nd\, 2022\, 11:00-13:00 | Session 3a. Models\, biomarkers and assays for systemic and immune toxicity \n“Biocompatibility of medical devices: eye irritation of preserved and unpreserved eye drops on HCE model”\nSpeaker:  Dr Laura Ceriotti @VitroScreen \nThursday\, November 24th\, 2022\, 11:00-12:40| Session 8a – In vitro methods for safety assessment of medical devices \n\n\nPosters\n\n\nJoint poster with Sonova: #307 – “In vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices”\nPoster presentation by Dr Rose-Marie Jenvert @SenzaGen \nSession 8a. In vitro methods for safety assessment of medical devices \nJoint poster with Coty: #275 – “Effect of a modulator on the skin sensitization potency of cosmetic fragrance formulations”\nPoster presentation by Dr Carine Linossier @Coty \nSession 4b. Local toxicity testing (safety and efficacy) \n  \n 
URL:https://senzagen.com/event/2022-estiv/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/ESTIV_Screenshot-2022-08-25.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221019
DTEND;VALUE=DATE:20221022
DTSTAMP:20260429T170211
CREATED:20220825T135715Z
LAST-MODIFIED:20220825T135806Z
UID:29760-1666137600-1666396799@senzagen.com
SUMMARY:2022 ASCCT
DESCRIPTION:Oct 19-21 | Chapel Hill\, N.C.\,USA\nMore information coming soon!
URL:https://senzagen.com/event/2022-ascct/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/22179-RAD-ASCCT-11th-Annual-Meeting-Graphics-Banner-CROPPED-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221007
DTSTAMP:20260429T170211
CREATED:20220707T081238Z
LAST-MODIFIED:20220926T135947Z
UID:29631-1664928000-1665100799@senzagen.com
SUMMARY:2022 Biocompatibility Matters
DESCRIPTION:Oct 5-6 | Copenhagen\, Denmark\nMeet SenzaGen at 2022 Biocompatibility Matters\, a two-day conference in Copenhagen. SenzaGen’s Medical Device specialist and ISO expert Dr Rose-Marie Jenvert will speak on the topic “New approaches to in vitro sensitization – regulatory acceptance”. \n\nKey takeaways:\n\n* An introduction to in vitro assays for skin sensitization\, ISO 10993-10\n* The potential to use polar and non-polar extracts in in vitro assays\n* How in vitro assays can gain regulatory acceptance\n* Case studies on in vitro skin sensitization assessment of medical devices \n\nRead more and register\n\n 
URL:https://senzagen.com/event/2022-biocompatibility-matters/
LOCATION:Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/07/BM-logo@2x-e1622186428171.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220922
DTSTAMP:20260429T170211
CREATED:20220427T123124Z
LAST-MODIFIED:20220916T085253Z
UID:29390-1663718400-1663804799@senzagen.com
SUMMARY:2022 ICT/IUTOX/EUROTOX
DESCRIPTION:2022 International Congress of Toxicology – “Uniting in Toxicology”\n\nDiscussions at this year’s ICT\nNew opportunities for skin sensitization testing with GARDskin OECD TG 442E\n\nCome visit us at our booth and join our industry symposium to learn how the high performance and broad applicability of the GARDskin method bring new opportunities to the field of in vitro skin sensitization testing. We will provide user cases to show how GARD can be used to fill data gaps during regulatory testing and R&D. \n\nIndustry symposium\nNew GARD data on “difficult-to-test” substances and potency assessment\n\nSep 20\, 12:00-13:00 CEST @Room 0.09 Athens\n \nREGISTER HERE TO SECURE YOUR SEAT\n(click the link or fill out the form below)\nFill out my online form.\n \n\nHighlights at our booth #34\nDiscover our expanded in vitro toxicity testing services\n\nDo you have “difficult-to-test” samples or are you looking for quantitative skin sensitizing potency information? Come discuss your testing needs with us and learn more about GARD and our expanded in vitro toxicity testing services for cosmetics\, chemicals and medical devices. \nFIND OUT ABOUT OUR SERVICES AND EXPERTISE
URL:https://senzagen.com/event/2022-ict-iutox-eurotox/
LOCATION:Maastricht
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/04/LIME-banner-v7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220914T143000
DTEND;TZID=Europe/Stockholm:20220914T180000
DTSTAMP:20260429T170211
CREATED:20220825T134032Z
LAST-MODIFIED:20220826T062417Z
UID:29741-1663165800-1663178400@senzagen.com
SUMMARY:2022 MVA MedTech Network meeting
DESCRIPTION:Drug device combination products and substance-based medical devices\nSep 14 | Copenhagen\, Denmark\nMedicon Valley Alliance\, together with member company Innokas Medical\, have the pleasure to invite you to the Medicon Valley Alliance MedTech Network meeting\, on the 14th of September\, focusing on drug-device combination products and substance-based medical devices. \n\nSign up here\n\nThe market for drug-device combination products is growing and it is anticipated that up to one in three medical products in development is a combination of a drug/substance and a MedTech product. Drivers for the growth in combination products is the rise of patients suffering from chronic diseases such as diabetes\, cancer\, and respiratory problems as well as growth in the home-based health care market and technological advancements. \nWhen searching for the correct regulatory approval in the EU the primary mode of action (PMOA) will define the regulatory path for your products. For example\, if the action of your medicinal substance is ancillary\, then your product is regulated as a medical device under MDR\, on the other hand\, if the product is mainly of the medicinal substance the product will be regulated as a medicinal product.  A substance with a therapeutic effect can be either a medicinal product/drug or a medical device\, depending on its primary mechanism of action. \nDeveloping this type of products is associated with a high level of complexity. For combination products\, you need to navigate two of the most intensely regulated pathways in one go: for pharmaceuticals and medical devices. The re-classification of substance-based medical devices according to MDR means a more extensive risk assessment involving scientific evidence of PMOA. \nIn this MVA MedTech Network meeting\, we would like to invite you to hear from experts in the area of developing drug-device combination products and substance-based medical devices as well as hearing from companies sharing their experiences\, challenges and solutions.\nIf you are interested in sharing your company’s approach and experiences with drug-device combination products and/or substance-based medical devices and to speak at the meeting on the 14th of September\, please reach out to Sofia Norås\, sn@mva.org. \nAgenda\n14.30 – 15.00  Registration\, networking and light refreshments\n15.00 – 15.10  Welcome\, Anette Steenberg\, CEO\, Medicon Valley Alliance; Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.10 – 15.15  IP and patents in combination products\, Pernille Winding Gojkovic\, CEO\, Høiberg European Patent Attorneys\n15.15 – 15.45  Challenging development with combination products\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.45 – 16.05  Substance-based medical devices\, Rose-Marie Jenvert\, Product Manager GARD applications SenzaGen\n16.05 – 16.40  Company cases TBC\n16.40 – 17.00  Concluding remarks: Building collaborations between organisations & Q&A to all speakers\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n17.00 – 18.00  Networking
URL:https://senzagen.com/event/2022-mva-medtech-network-meeting/
LOCATION:Medicon Valley Alliance\, Auditorium\, Arne Jacobsens Alle 15 \, 2300 Ørestad City\, Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/220914-medtech-network-banner-1080.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260429T170211
CREATED:20220224T104229Z
LAST-MODIFIED:20220224T105153Z
UID:28967-1649116800-1649375999@senzagen.com
SUMMARY:in-cosmetics Global
DESCRIPTION:The leading global event for personal care ingredients\nApril 5-7 | Porte de Versailles\, Paris | Booth: P102\nMeet SenzaGen and partners PKDERM\, GenEvolutioN\, WatchFrog and CEHTRA at in-cosmetics Global in Paris to find out about our latest innovations for safety and efficacy evaluation of cosmetics and ingredients!
URL:https://senzagen.com/event/in-cosmetics-global-2/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/02/Incosmeticsglobal-2022_1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220327
DTEND;VALUE=DATE:20220401
DTSTAMP:20260429T170211
CREATED:20211209T133110Z
LAST-MODIFIED:20220321T111837Z
UID:28283-1648339200-1648771199@senzagen.com
SUMMARY:2022 SOT
DESCRIPTION:Meet us at the 2022 SOT Annual Meeting & ToxExpo\nBooth #1207 @ San Diego Convention Center\, San Diego\, USA\nAre you attending the 2021 Society of Toxicology Annual Meeting? Come join our hosted session and poster presentations to hear the latest news about GARD™ and how the assays are used for skin sensitization testing. We will also introduce you to how you can use in vitro methods for the biological evaluation of medical devices.  \n\nExhibitor hosted session\n\nMar 29\, 10:30-11:30 EDT\, Room 23A\nNew GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals:\nTogether with guest speakers from Takasago and Sonova\, our Scientific Liaison Dr Andy Forreryd will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. \n  \n \nBook mark the session in SOT’s event calendar: \nSkin Sensitization: Using In Vitro Tools for Quantitative Potency Assessment as an Alternative to the Local Lymph Node Assay \n  \n\nPosters\n\nLive poster sessions on Mar 28\, 9:00-10:45 EDT\n🎫 P460 | Applicability domain of GARDskin\nThe GARDskin assay: Investigation of the applicability domain of indirectly acting haptens  \n🎫 P850 | Joint poster with Sonova\nIn vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices  \n🎫 P846 | Joint poster with Risk Science Consortium\nAbility of the GARD assay to replace the GPMT and the LLNA for assessment of the skin sensitization potential of medical devices  \n 
URL:https://senzagen.com/event/2022-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/SOT-2022_small-narrow-green.png
END:VEVENT
END:VCALENDAR